Compare GMEX & BBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMEX | BBLG |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 1.2M |
| IPO Year | 2022 | 2014 |
| Metric | GMEX | BBLG |
|---|---|---|
| Price | $1.34 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 481.5K | 45.3K |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | $2.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.39 |
| 52 Week High | $4.57 | $5.32 |
| Indicator | GMEX | BBLG |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 14.72 |
| Support Level | $1.25 | N/A |
| Resistance Level | $2.24 | $1.18 |
| Average True Range (ATR) | 0.41 | 0.06 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 2.54 | 1.52 |
GMEX Robotics Corp is engaged in the design and deployment of AI-powered robotics and intelligent consumer technologies. The group operates in three business areas: Consumer and Commercial Robotics: Developing intuitive and interactive robots designed to assist with daily tasks, provide smart home integration, and offer new levels of convenience and connectivity to boost productivity; AI-Driven Hardware: Embedding artificial intelligence into physical products to create self-learning and adaptive user experiences; and Innovation & Ecosystem: Building a robust ecosystem of robotic products that communicate and evolve, powered by proprietary AI algorithms.
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.